Related Experiment Video

Updated: Dec 1, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.7K

Long non-coding RNA MAFG-AS1 knockdown blocks malignant progression in breast cancer cells by inactivating JAK2/STAT3

Mingxing Ding1, Yongqiang Fu1, Fangming Guo1

  • 1Medical Molecular Biology Laboratory, Medical College, Jinhua Polytechnic Jinhua, Zhejiang, China.

International Journal of Clinical and Experimental Pathology
|November 9, 2020
PubMed
Abstract

Insights

Knocking down long non-coding RNA MAFG-antisense 1 (MAFG-AS1) inhibits breast cancer progression by targeting the miR-3196/TFAP2A axis and suppressing the JAK2/STAT3 pathway both in vitro and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Breast cancer remains a significant global health threat to women.
  • Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development and progression.
  • The specific function of lncRNA MAFG-antisense 1 (MAFG-AS1) in breast cancer requires elucidation.

Purpose of the Study:

  • To investigate the role of lncRNA MAFG-AS1 in breast cancer.
  • To explore the underlying molecular mechanisms by which MAFG-AS1 influences breast cancer progression.

Main Methods:

  • Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of MAFG-AS1, miR-3196, and TFAP2A.
  • Cell proliferation, colony formation, apoptosis, and glycolysis were assessed using MTT assays, colony formation assays, flow cytometry, and measurements of glucose consumption/lactate production, respectively.
  • Western blotting quantified protein levels, dual-luciferase reporter assays confirmed molecular interactions, and in vivo tumor formation assays in nude mice evaluated MAFG-AS1's role in vivo.

Main Results:

  • MAFG-AS1 expression was elevated in breast tumor tissues and cells.
  • MAFG-AS1 knockdown inhibited cell proliferation, colony formation, and glycolysis, while promoting apoptosis.
  • MAFG-AS1 regulates miR-3196, which in turn targets TFAP2A, and this axis impacts the JAK2/STAT3 signaling pathway, ultimately reducing tumor growth in vivo.

Conclusions:

  • MAFG-AS1 knockdown significantly attenuates breast cancer progression both in vitro and in vivo.
  • The MAFG-AS1/miR-3196/TFAP2A regulatory axis plays a crucial role in breast cancer.
  • MAFG-AS1 knockdown inhibits breast cancer by suppressing the JAK2/STAT3 signaling pathway via this regulatory axis.
Keywords:
JAK2/STAT3MAFG-AS1TFAP2Abreast cancermiR-3196

More Related Videos

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays11:05

Investigation of Genetic Dependencies Using CRISPR-Cas9-based Competition Assays

Published on: January 7, 2019

9.8K
The Soft Agar Colony Formation Assay08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

113.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.3K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.5K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
23.4K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.9K